Laboratory study reveals that threonine 348 controls the subcellular localization of the tumor suppressor PTEN, indicating a key regulatory mechanism for its compartmentalized functions.
The tumor suppressor PTEN (phosphatase and tensin homolog) dephosphorylates PIP 3 (phosphatidylinositol (3,4,5)‐trisphosphate) at the plasma membrane and protects genomic integrity in the nucleus; thus, regulation of PTEN subcellular localization is crucial. Previous studies have shown that the PTEN 350 fragment is markedly enriched in the nucleus, a feature not explained by the N‐terminal nuclear localization signal. In this study, we generated PTEN fragments of various lengths and identified PTEN 348 (residues 1–348), which showed prominent nuclear localization. Furthermore, the replacement of threonine 348 (Thr348) with other amino acids reduced the nuclear localization of the PTEN 348 and PTEN 350 fragments. Moreover, we found that PTEN A4 and PTEN K13R,A4 localized predominantly to the nucleus and plasma membrane, respectively, and that substitution of Thr348 with aspartic acid resulted in cytoplasmic localization in both mutants. Collectively, these results indicate that Thr348 is a key contributor to the regulation of PTEN subcellular localization.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: